Last reviewed · How we verify

NCT03584204: SLIM

Skeletal Muscle Parameters of Liver Cirrhosis in Non-invasive Imaging and Outcome

Recruiting now Last updated 5 October 2021
What this trial tests

trial testing imaging in Liver Cirrhosis in 400 participants. Currently enrolling.

Timeline
1 January 2018
Primary endpoint
31 July 2025
31 August 2026

Quick facts

Lead sponsorUniversity Hospital, Bonn
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment400
Start date1 January 2018
Primary completion31 July 2025
Estimated completion31 August 2026
Sites3 locations across Italy, Germany

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Bonn

Who can join

Adults 18 to 80, any sex, with Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The principal aim of this study is to analyse L3-SMI (skeletal muscle index) in a cohort of patients with decompensated liver cirrhosis and TIPS (transjugular intrahepatic portosystemic shunt), and compare the prognostic power with TPMT (transverse psoas muscle thickness). Furthermore, the role of myosteatosis, determined in CT by L3-SMI, MRI and ultrasound will be studied.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt.
    Praktiknjo M, Clees C, Pigliacelli A, Fischer S, et al · · 2019 · cited 95× · PMID 30939488 · DOI 10.14309/ctg.0000000000000025
  2. Combination of Fat-Free Muscle Index and Total Spontaneous Portosystemic Shunt Area Identifies High-Risk Cirrhosis Patients.
    Faron A, Abu-Omar J, Chang J, Böhling N, et al · · 2022 · cited 9× · PMID 35492329 · DOI 10.3389/fmed.2022.831005
  3. Ultrasound-Defined Sarcopenia Independently Predicts Acute Decompensation in Advanced Chronic Liver Disease.
    Gödiker J, Schwind L, Jacob T, Böhling N, et al · · 2024 · cited 8× · PMID 39529225 · DOI 10.1002/jcsm.13630
  4. Myosteatosis independently predicts transplant-free survival in patients with primary sclerosing cholangitis.
    Praktiknjo M, Zhou T, Krüsken M, Jacob T, et al · · 2023 · cited 6× · PMID 37586906 · DOI 10.1016/j.dld.2023.08.037
  5. Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis.
    Queck A, Thomas D, Jansen C, Schreiber Y, et al · · 2019 · cited 6× · PMID 31644538 · DOI 10.1371/journal.pone.0222840

Verify or expand the search:

Other trials of imaging

Trials testing the same drug.

Other recruiting trials for Liver Cirrhosis

Currently open trials in the same condition.

Other University Hospital, Bonn trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03584204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing